Moneycontrol
Get App
SENSEX NIFTY
YOU ARE HERE > MONEYCONTROL > MARKETS > PRINTING & STATIONERY > News - Navneet Education

Navneet Education

BSE: 508989|NSE: NAVNETEDUL|ISIN: INE060A01024|SECTOR: Printing & Stationery
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Jan 22, 16:00
98.00
-0.25 (-0.25%)
VOLUME 2,540
LIVE
NSE
Jan 22, 15:59
98.05
-0.35 (-0.36%)
VOLUME 31,267
News on Navneet Education
Select Year: 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2000-2005
Overall margin guidance of 20-25%: Nicholas Piramal

12.24 pm | 27 Dec 2005

Nicholas Piramal has signed a seven year R&D pact with Pfizer International. Chairman at Nicholas Piramal Ajay Piramal says that their overall margin ...

Nicholas Piramal, 10-year manufacturing & supply agreement

2.23 pm | 24 Nov 2005

Nicholas Piramal India Limited announces 10-year Manufacturing and Supply Agreement...

GlaxoSmithKline prepares to bring bird-flu drug to India

9.59 am | 23 Nov 2005

Relenza was not an anti-viral medicine that GlaxoSmithKline (GSK) was planning to register in India. But with bird-flu putting the global spotlight on...

NPIL - announcement : custom manufacturing group head

2.32 pm | 16 Nov 2005

Nicholas Piramal India Limited - announcement:custom manufacturing group head...

Aberdeen holds four stocks in healthcare sector

3.28 pm | 08 Nov 2005

Adrian Lim of Aberdeen Asset Management is holding four stocks in healthcare sector....

Nicholas Piramal acquires Avecia Pharmaceuticals, UK

2.39 pm | 27 Oct 2005

Nicholas Piramal acquires Avecia Pharmaceuticals, UK for a consideration of GBP 9.5 million...

AstraZeneca and Nicholas Piramal announce Development

10.44 am | 27 Oct 2005

AstraZeneca and Nicholas Piramal announce Development and Know-how agreement...

AstraZeneca & Nicholas Piramal announce agreement

2.45 pm | 26 Oct 2005

AstraZeneca & Nicholas Piramal announce Development & Know-how agreement...

Input cost increase not a concern: Navneet

3.48 pm | 24 Oct 2005

Navneet Publications has come out with its numbers and Director-Finance at Navneet Publications, Sunil Gala says that the company will not be impacted...

Navneet Publications Q2 net profit at Rs 2cr

12.15 pm | 24 Oct 2005

Navneet Publications has announced its second quarter results. The company's Q2 net profit is down at Rs 2 crore from Rs 2.93 crore....

Navneet has target of Rs 380, says Gaba

2.25 pm | 21 Oct 2005

Technical Analyst, Prakash Gaba, feels that Navneet has technical target of Rs 380....

Nicholas Piramal reports audited Q2 FY2006 results

2.49 pm | 20 Oct 2005

Nicholas Piramal reports audited Q2 FY2006 results; sales down 2.0% to Rs. 3.5 billion, net profit up by 0.9% to Rs. 549.0 million...

Brokers optimistic about Navneet Publications

1.46 pm | 24 Aug 2005

Broking houses are bullish on Navneet Publications (India). SSKI has recommended 'Buy rating' on the company. It has a target price of Rs 405....

Huge corporate losses due to Mumbai deluge

10.14 am | 29 Jul 2005

Corporate India has started assessing the damage done due to the floods caused in Mumbai. Industry bodies are expecting a loss of nearly Rs 1,000- 2,5...

NPlL invests 17% equity in Canadian Biotech Reearch

2.55 pm | 07 Jul 2005

Nicholas Piramal India Limited Invests 17% equity in Canadian Biotech Research Company - Biosyntech, Inc....

Sale promos to be impacted: Nicholas Piramal

3.53 pm | 03 May 2005

Sales promotion in pharma companies will be an issue where the fine print will have to be looked at carefully. ...

Hold Nicholas Piramal, it is a fair play

12.38 pm | 03 Mar 2005

Alok Bahl is of the view that Nicholas Piramal is a fair play and investors should hold the stock. ...

Nicholas Piramal is a steady investment

3.09 pm | 22 Feb 2005

Anup Bagchi is of the view that Nicholas Piramal is a steady investment....

Exit Nicholas Piramal if breaks Rs 240: Gaba

2.16 pm | 10 Feb 2005

Prakash Gaba feels that investors should exit Nicholas Piramal if it breaks Rs 240. ...

Hold Nicholas Piramal; buy Ranbaxy on dips

10.21 am | 11 Jan 2005

E Mathew is of the view that investors should hold Nicholas Piramal with a stoploss of Rs 260-264. They can also buy Ranbaxy Labs on dips....

1
Quick Links for Navneet Education
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.